NCT04101474View on ClinicalTrials.gov

Role Of Ketamine in Treatment-Resistant Major Depressive Disorder And Its Effect on Suicidality

NACompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

October 1, 2021

Study Completion Date

October 1, 2021

Conditions
Treatment Resistant Depression
Interventions
DRUG

Ketamine

Ketamine is a high-affinity, noncompetitive N-methyl-D- aspartate (NMDA) glutamate receptor antagonist it has been used in anesthesiology for more than 50 years the time course of antidepressant response to ketamine is characterized by an initial reduction in depressive symptoms within 2 h

Trial Locations (1)

Unknown

Assiut university, Asyut

All Listed Sponsors
lead

Assiut University

OTHER

NCT04101474 - Role Of Ketamine in Treatment-Resistant Major Depressive Disorder And Its Effect on Suicidality | Biotech Hunter | Biotech Hunter